Advanced search
Publication Cover
Leukemia & Lymphoma Volume 35, 1999 - Issue 5-6
Submit an article Journal homepage
36
Views
30
CrossRef citations to date
0
Altmetric
LetterToEditor Article

Rapid Regression of Chemotherapy Refractory Lymphocyte Predominant Hodgkin's Disease after Administration of Rituximab (anti CD 20 Monoclonal Antibody) and Interleukin-2

Ulrich Keilholz Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany
,
Hubert Szelényi Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany
,
Jan Siehl Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany
,
Hans Dieter Foss Dept. of Pathology, University Hospital Benjamin Franklin, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany
,
Wolfgang Knauf Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany
&
Eckhard Thiel Dept. of Hematology/Oncology, Free University Berlin, Hindenburgdamm 30, 12200, Berlin, Germany
Pages 641-642 | Received 30 May 1999, Published online: 30 Mar 2010

Citations (30)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Yue Liu, Yanlan Wang, Jieyu Xing, Yumei Li, Jiayu Liu & Zhong Wang. (2018) A novel multifunctional anti-CEA-IL15 molecule displays potent antitumor activities. Drug Design, Development and Therapy 12, pages 2645-2654.
Read now
Martine van Grotel, King H. Lam, Rogier de Man, Auke Beishuizen, Rob Pieters & Marry M. van den Heuvel-EiBrink. (2006) High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only. Leukemia & Lymphoma 47:8, pages 1504-1510.
Read now
A. Unal, I. Sari, K. Deniz, M. Ozkan, O. Kontas, B. Eser & M. Cetin. (2005) Familial nodular lymphocyte predominant Hodgkin lymphoma: Successful treatment with CHOP plus rituximab. Leukemia & Lymphoma 46:11, pages 1613-1617.
Read now

Articles from other publishers (27)

Brian D. Friend, Ibrahim N. Muhsen, Shreeya Patel, LaQuisa C. Hill, Premal Lulla, Carlos A. Ramos, S. Ravi Pingali, Rammurti T. Kamble, Tami D. John, Baheyeldin Salem, Saleh Bhar, Erin E. Doherty, John Craddock, Ghadir Sasa, Mengfen Wu, Tao Wang, Caridad Martinez, Robert A. Krance, Helen E. Heslop & George Carrum. (2022) Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma. Bone Marrow Transplantation 57:4, pages 579-585.
Crossref
Thomas A. Waldmann. (2015) The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy. Cancer Immunology Research 3:3, pages 219-227.
Crossref
Bruno Bockorny, Ion Codreanu & Constantin A. Dasanu. (2012) Hodgkin lymphoma as Richter transformation in chronic lymphocytic leukaemia: a retrospective analysis of world literature. British Journal of Haematology 156:1, pages 50-66.
Crossref
Kamal S. Saini, Hatem A. AzimJr.Jr., Emilia Cocorocchio, Anna Vanazzi, Monika Lamba Saini, Paola Rafaniello Raviele, Giancarlo Pruneri & Fedro A. Peccatori. (2011) Rituximab in Hodgkin lymphoma: Is the target always a hit?. Cancer Treatment Reviews 37:5, pages 385-390.
Crossref
Lauren S Maeda & Ranjana H Advani. (2009) The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma. Current Opinion in Oncology 21:5, pages 397-400.
Crossref
Alfred Ian Lee & Ann S. LaCasce. (2009) Nodular Lymphocyte Predominant Hodgkin Lymphoma. The Oncologist 14:7, pages 739-751.
Crossref
Daniel Re, Thomas Elter & Michael Hallek. (2007) Report on the 1st International Workshop of the German Competence Network Malignant Lymphomas. Oncology Research and Treatment 30:5, pages 265-273.
Crossref
Raphael Clynes. (2006) Antitumor Antibodies in the Treatment of Cancer: Fc Receptors Link Opsonic Antibody with Cellular Immunity. Hematology/Oncology Clinics of North America 20:3, pages 585-612.
Crossref
Wolfgang Dörffel & Günther Schellong. 2006. Pädiatrische Hämatologie und Onkologie. Pädiatrische Hämatologie und Onkologie 752 769 .
Bruce Shiramizu, Sherrie L. Perkins, Sharon Bergeron, Mark Lones, Kara Kelly, Michael Weiner & Mitchell S. Cairo. (2004) Assessing Immunoglobulin Heavy Chain Rearrangements in Pediatric CD20-Positive and CD20-Negative Classic Hodgkin's Diseas. Clinical Lymphoma 5:3, pages 184-189.
Crossref
Arun Chakrabarty & Karl Beutner. (2004) Therapy of other viral infections: herpes to hepatitis. Dermatologic Therapy 17:6, pages 465-490.
Crossref
J.E. Davis & D.J. Moss. (2004) Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies. Tissue Antigens 63:4, pages 285-292.
Crossref
Thomas S. Lin & John C. Byrd. 2004. Treatment of Leukemia and Lymphoma. Treatment of Leukemia and Lymphoma 127 167 .
H. Hanenberg & U. Göbel. 2004. Therapie der Krankheiten im Kindes- und Jugendalter. Therapie der Krankheiten im Kindes- und Jugendalter 653 660 .
Thomas S. Lin, Margaret S. Lucas & John C. Byrd. 2004. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia 269 298 .
Bertram Schnitzer & Riccardo Valdez. 2004. Hematopathology in Oncology. Hematopathology in Oncology 259 290 .
Masato Kato, Seema Khan, Nelson Gonzalez, Brian P. O'Neill, Kylie J. McDonald, Ben J. Cooper, Nicola Z. Angel & Derek N.J. Hart. (2003) Hodgkin's Lymphoma Cell Lines Express a Fusion Protein Encoded by Intergenically Spliced mRNA for the Multilectin Receptor DEC-205 (CD205) and a Novel C-type Lectin Receptor DCL-1. Journal of Biological Chemistry 278:36, pages 34035-34041.
Crossref
B. PellegrinoM.J. Terrier-LacombeO. OberlinT. LeblancY. PerelY. BertrandC. BeardC. EdanC. SchmittD. PlantazH. PacquementJ.P. VannierC. LambillioteG. CouillaultA. Babin-BoilletotI. ThuretF. DemeocqG. LevergerG. DelsolJ. Landman-Parker. (2003) Lymphocyte-Predominant Hodgkin’s Lymphoma in Children: Therapeutic Abstention After Initial Lymph Node Resection—A Study of the French Society of Pediatric Oncology. Journal of Clinical Oncology 21:15, pages 2948-2952.
Crossref
Bradley C. EkstrandJennifer B. LucasSteven M. HorwitzZhen FanSheila BreslinRichard T. HoppeYasodha NatkunamNancy L. BartlettSandra J. Horning. (2003) Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 101:11, pages 4285-4289.
Crossref
Ute RehwaldHolger SchulzMarcel ReiserMarkus SieberJan Oliver StaakFranck MorschhauserChristoph DriessenThomas RüdigerKonrad Müller-HermelinkVolker DiehlAndreas Engert. (2003) Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101:2, pages 420-424.
Crossref
Volker Diehl, Harald Stein, Michael Hummel, Raphael Zollinger & Joseph M. Connors. (2003) Hodgkin’s Lymphoma: Biology and Treatment Strategies for Primary, Refractory, and Relapsed Disease. Hematology 2003:1, pages 225-247.
Crossref
E. Boulanger, V. Meignin, G. Leverger & P. Solal-Céligny. (2003) Rituximab monotherapy in nodular lymphocyte-predominant Hodgkin’s disease. Annals of Oncology 14:1, pages 171.
Crossref
Bradley C. Ekstrand & Sandra J. Horning. (2002) Lymphocyte predominant Hodgkin’s disease. Current Oncology Reports 4:5, pages 424-433.
Crossref
Angelia Gibson, Heather DeGrendele, Mark S. Kaminski & James W. Lynch. (2002) Highlights from: 38th Annual Meeting of the American Society of Clinical Oncology May 18–21, 2002; Orlando, Florida. Clinical Lymphoma 3:1, pages 12-17.
Crossref
Todd A Fehniger, Megan A Cooper & Michael A Caligiuri. (2002) Interleukin-2 and interleukin-15: immunotherapy for cancer. Cytokine & Growth Factor Reviews 13:2, pages 169-183.
Crossref
Paul M. Sondel & Jacquelyn A. Hank. (2001) ANTIBODY-DIRECTED, EFFECTOR CELL-MEDIATED TUMOR DESTRUCTION. Hematology/Oncology Clinics of North America 15:4, pages 703-721.
Crossref
Joseph M. Connors, Evert M. Noordijk & Sandra J. Horning. (2001) Hodgkin's Lymphoma: Basing the Treatment on the Evidence. Hematology 2001:1, pages 178-193.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.